View Future GrowthCathay Biotech 過去の業績過去 基準チェック /46Cathay Biotechの収益は年間平均-2.2%の割合で減少していますが、 Chemicals業界の収益は年間 減少しています。収益は年間5.6% 10.9%割合で 増加しています。 Cathay Biotechの自己資本利益率は2.7%であり、純利益率は17.4%です。主要情報-2.22%収益成長率-5.21%EPS成長率Chemicals 業界の成長12.10%収益成長率10.89%株主資本利益率2.65%ネット・マージン17.37%前回の決算情報31 Mar 2026最近の業績更新お知らせ • Mar 30Cathay Biotech Inc. to Report Q1, 2026 Results on Apr 30, 2026Cathay Biotech Inc. announced that they will report Q1, 2026 results on Apr 30, 2026お知らせ • Dec 26Cathay Biotech Inc. to Report Fiscal Year 2025 Results on Apr 24, 2026Cathay Biotech Inc. announced that they will report fiscal year 2025 results on Apr 24, 2026お知らせ • Sep 30Cathay Biotech Inc. to Report Q3, 2025 Results on Oct 31, 2025Cathay Biotech Inc. announced that they will report Q3, 2025 results on Oct 31, 2025お知らせ • Jun 30Cathay Biotech Inc. to Report First Half, 2025 Results on Aug 16, 2025Cathay Biotech Inc. announced that they will report first half, 2025 results on Aug 16, 2025お知らせ • Mar 28Cathay Biotech Inc. to Report Q1, 2025 Results on Apr 30, 2025Cathay Biotech Inc. announced that they will report Q1, 2025 results on Apr 30, 2025お知らせ • Dec 27Cathay Biotech Inc. to Report Fiscal Year 2024 Results on Apr 03, 2025Cathay Biotech Inc. announced that they will report fiscal year 2024 results on Apr 03, 2025すべての更新を表示Recent updatesBoard Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Xiang Yang Wu was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Mar 30Cathay Biotech Inc. to Report Q1, 2026 Results on Apr 30, 2026Cathay Biotech Inc. announced that they will report Q1, 2026 results on Apr 30, 2026お知らせ • Dec 26Cathay Biotech Inc. to Report Fiscal Year 2025 Results on Apr 24, 2026Cathay Biotech Inc. announced that they will report fiscal year 2025 results on Apr 24, 2026お知らせ • Sep 30Cathay Biotech Inc. to Report Q3, 2025 Results on Oct 31, 2025Cathay Biotech Inc. announced that they will report Q3, 2025 results on Oct 31, 2025お知らせ • Jun 30Cathay Biotech Inc. to Report First Half, 2025 Results on Aug 16, 2025Cathay Biotech Inc. announced that they will report first half, 2025 results on Aug 16, 2025お知らせ • Jun 04Cathay Biotech Inc., Annual General Meeting, Jun 27, 2025Cathay Biotech Inc., Annual General Meeting, Jun 27, 2025, at 14:00 China Standard Time. Location: 9F, No. 11, Lane 396, Lvzhou Ring Road, Minhang District, Shanghai Chinaお知らせ • Mar 28Cathay Biotech Inc. to Report Q1, 2025 Results on Apr 30, 2025Cathay Biotech Inc. announced that they will report Q1, 2025 results on Apr 30, 2025お知らせ • Dec 27Cathay Biotech Inc. to Report Fiscal Year 2024 Results on Apr 03, 2025Cathay Biotech Inc. announced that they will report fiscal year 2024 results on Apr 03, 2025Reported Earnings • Oct 31Third quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.13 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.17 (up from CN¥0.13 in 3Q 2023). Revenue: CN¥770.8m (up 44% from 3Q 2023). Net income: CN¥97.7m (up 36% from 3Q 2023). Profit margin: 13% (in line with 3Q 2023).お知らせ • Oct 22Cathay Biotech Inc. (SHSE:688065) announces an Equity Buyback for CNY 20 million worth of its shares.Cathay Biotech Inc. announces a share repurchase program. Under the program, the company will repurchase up to CNY 20 million worth of its shares. The shares will be repurchased at a price of not more than CNY 67 per share. The repurchased shares will be used for employee stock ownership plans or equity incentives. Repurchases will be funded using company's own funds or self-raised funds. The program will be valid till 12 months from approval of board.Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to CN¥46.38, the stock trades at a trailing P/E ratio of 72.5x. Average trailing P/E is 31x in the Chemicals industry in China. Total loss to shareholders of 13% over the past year.お知らせ • Sep 30Cathay Biotech Inc. to Report Q3, 2024 Results on Oct 31, 2024Cathay Biotech Inc. announced that they will report Q3, 2024 results on Oct 31, 2024Valuation Update With 7 Day Price Move • Sep 27Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥38.08, the stock trades at a trailing P/E ratio of 63.6x. Average trailing P/E is 29x in the Chemicals industry in China. Total loss to shareholders of 31% over the past year.Reported Earnings • Aug 16Second quarter 2024 earnings released: EPS: CN¥0.24 (vs CN¥0.30 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.24 (down from CN¥0.30 in 2Q 2023). Revenue: CN¥759.8m (up 45% from 2Q 2023). Net income: CN¥142.2m (down 23% from 2Q 2023). Profit margin: 19% (down from 35% in 2Q 2023). The decrease in margin was driven by higher expenses.お知らせ • Jun 28Cathay Biotech Inc. to Report First Half, 2024 Results on Aug 31, 2024Cathay Biotech Inc. announced that they will report first half, 2024 results on Aug 31, 2024お知らせ • Jun 06Cathay Biotech Inc., Annual General Meeting, Jun 27, 2024Cathay Biotech Inc., Annual General Meeting, Jun 27, 2024, at 14:00 China Standard Time. Location: 9F, No. 11, Lane 396, Lvzhou Ring Road, Minhang District, Shanghai ChinaReported Earnings • May 01First quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.10 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.18 (up from CN¥0.10 in 1Q 2023). Revenue: CN¥684.5m (up 35% from 1Q 2023). Net income: CN¥105.3m (up 83% from 1Q 2023). Profit margin: 15% (up from 11% in 1Q 2023). The increase in margin was driven by higher revenue.Valuation Update With 7 Day Price Move • Apr 29Investor sentiment improves as stock rises 21%After last week's 21% share price gain to CN¥49.16, the stock trades at a trailing P/E ratio of 78.1x. Average trailing P/E is 32x in the Chemicals industry in China. Total loss to shareholders of 7.2% over the past year.New Risk • Apr 09New major risk - Revenue and earnings growthEarnings have declined by 0.06% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.お知らせ • Mar 30Cathay Biotech Inc. to Report Q1, 2024 Results on Apr 30, 2024Cathay Biotech Inc. announced that they will report Q1, 2024 results on Apr 30, 2024Reported Earnings • Feb 24Full year 2023 earnings released: EPS: CN¥0.63 (vs CN¥0.95 in FY 2022)Full year 2023 results: EPS: CN¥0.63 (down from CN¥0.95 in FY 2022). Revenue: CN¥2.11b (down 13% from FY 2022). Net income: CN¥367.0m (down 34% from FY 2022). Profit margin: 17% (down from 23% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 49% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Chemicals industry in China.お知らせ • Dec 29Cathay Biotech Inc. to Report Fiscal Year 2023 Results on Apr 30, 2024Cathay Biotech Inc. announced that they will report fiscal year 2023 results on Apr 30, 2024Reported Earnings • Nov 02Third quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.25 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.13 (down from CN¥0.25 in 3Q 2022). Revenue: CN¥535.1m (down 2.5% from 3Q 2022). Net income: CN¥72.0m (down 52% from 3Q 2022). Profit margin: 14% (down from 27% in 3Q 2022). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 53% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Chemicals industry in China.お知らせ • Aug 18Cathay Biotech Inc. (SHSE:688065) announces an Equity Buyback for CNY 100 million worth of its shares.Cathay Biotech Inc. announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The program will be valid for a period of 12 months.Reported Earnings • Aug 08Second quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.28 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.30 (up from CN¥0.28 in 2Q 2022). Revenue: CN¥525.0m (down 16% from 2Q 2022). Net income: CN¥184.4m (up 14% from 2Q 2022). Profit margin: 35% (up from 26% in 2Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China.お知らせ • Jun 28Cathay Biotech Inc. to Report First Half, 2023 Results on Aug 16, 2023Cathay Biotech Inc. announced that they will report first half, 2023 results on Aug 16, 2023お知らせ • Jun 27Cathay Biotech Inc. announced that it expects to receive CNY 6.6 billion in funding from China Merchants Group LimitedCathay Biotech Inc. announced a private placement of common shares for gross proceeds up to CNY 6,600 million on June 25, 2023. The transaction will include participation from new investor China Merchants Group Limited. The transaction is subject to the approval of shareholders of the company.Reported Earnings • Apr 26Full year 2022 earnings released: EPS: CN¥0.95 (vs CN¥1.04 in FY 2021)Full year 2022 results: EPS: CN¥0.95 (down from CN¥1.04 in FY 2021). Revenue: CN¥2.44b (up 11% from FY 2021). Net income: CN¥553.3m (down 9.0% from FY 2021). Profit margin: 23% (down from 28% in FY 2021). The decrease in margin was driven by higher expenses.Board Change • Mar 15Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. 3 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.収支内訳Cathay Biotech の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史XSSC:688065 収益、費用、利益 ( )CNY Millions日付収益収益G+A経費研究開発費31 Mar 263,39458925423431 Dec 253,29556124623830 Sep 253,28859424224330 Jun 253,18455023625631 Mar 253,04952122824931 Dec 242,95848922523330 Sep 242,76439823823230 Jun 242,52837222720331 Mar 242,29341419818431 Dec 232,11436721518930 Sep 232,16938123517930 Jun 232,18345925618731 Mar 232,28543627019931 Dec 222,44155323918830 Sep 222,44760520718430 Jun 222,51761918816431 Mar 222,53862818214531 Dec 212,36359518113430 Sep 212,09961214311830 Jun 211,8395641479931 Mar 211,5794811449731 Dec 201,4974581468430 Sep 201,4824281817030 Jun 201,6014322034131 Mar 201,72247525810531 Dec 191,9164792129031 Dec 181,7574661858631 Dec 171,3633331316531 Dec 1692914510538質の高い収益: 688065は 高品質の収益 を持っています。利益率の向上: 688065の現在の純利益率 (17.4%)は、昨年(17.1%)よりも高くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 688065の収益は過去 5 年間で年間2.2%減少しました。成長の加速: 688065の過去 1 年間の収益成長率 ( 13.2% ) は、5 年間の平均 ( 年間-2.2%を上回っています。収益対業界: 688065の過去 1 年間の収益成長率 ( 13.2% ) はChemicals業界3.7%を上回りました。株主資本利益率高いROE: 688065の 自己資本利益率 ( 2.7% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YMaterials 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/03 13:13終値2026/06/03 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cathay Biotech Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Junjun ZhuHaitong International Research LimitedTing Zhou ZhuangHuatai Research
お知らせ • Mar 30Cathay Biotech Inc. to Report Q1, 2026 Results on Apr 30, 2026Cathay Biotech Inc. announced that they will report Q1, 2026 results on Apr 30, 2026
お知らせ • Dec 26Cathay Biotech Inc. to Report Fiscal Year 2025 Results on Apr 24, 2026Cathay Biotech Inc. announced that they will report fiscal year 2025 results on Apr 24, 2026
お知らせ • Sep 30Cathay Biotech Inc. to Report Q3, 2025 Results on Oct 31, 2025Cathay Biotech Inc. announced that they will report Q3, 2025 results on Oct 31, 2025
お知らせ • Jun 30Cathay Biotech Inc. to Report First Half, 2025 Results on Aug 16, 2025Cathay Biotech Inc. announced that they will report first half, 2025 results on Aug 16, 2025
お知らせ • Mar 28Cathay Biotech Inc. to Report Q1, 2025 Results on Apr 30, 2025Cathay Biotech Inc. announced that they will report Q1, 2025 results on Apr 30, 2025
お知らせ • Dec 27Cathay Biotech Inc. to Report Fiscal Year 2024 Results on Apr 03, 2025Cathay Biotech Inc. announced that they will report fiscal year 2024 results on Apr 03, 2025
Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Xiang Yang Wu was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Mar 30Cathay Biotech Inc. to Report Q1, 2026 Results on Apr 30, 2026Cathay Biotech Inc. announced that they will report Q1, 2026 results on Apr 30, 2026
お知らせ • Dec 26Cathay Biotech Inc. to Report Fiscal Year 2025 Results on Apr 24, 2026Cathay Biotech Inc. announced that they will report fiscal year 2025 results on Apr 24, 2026
お知らせ • Sep 30Cathay Biotech Inc. to Report Q3, 2025 Results on Oct 31, 2025Cathay Biotech Inc. announced that they will report Q3, 2025 results on Oct 31, 2025
お知らせ • Jun 30Cathay Biotech Inc. to Report First Half, 2025 Results on Aug 16, 2025Cathay Biotech Inc. announced that they will report first half, 2025 results on Aug 16, 2025
お知らせ • Jun 04Cathay Biotech Inc., Annual General Meeting, Jun 27, 2025Cathay Biotech Inc., Annual General Meeting, Jun 27, 2025, at 14:00 China Standard Time. Location: 9F, No. 11, Lane 396, Lvzhou Ring Road, Minhang District, Shanghai China
お知らせ • Mar 28Cathay Biotech Inc. to Report Q1, 2025 Results on Apr 30, 2025Cathay Biotech Inc. announced that they will report Q1, 2025 results on Apr 30, 2025
お知らせ • Dec 27Cathay Biotech Inc. to Report Fiscal Year 2024 Results on Apr 03, 2025Cathay Biotech Inc. announced that they will report fiscal year 2024 results on Apr 03, 2025
Reported Earnings • Oct 31Third quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.13 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.17 (up from CN¥0.13 in 3Q 2023). Revenue: CN¥770.8m (up 44% from 3Q 2023). Net income: CN¥97.7m (up 36% from 3Q 2023). Profit margin: 13% (in line with 3Q 2023).
お知らせ • Oct 22Cathay Biotech Inc. (SHSE:688065) announces an Equity Buyback for CNY 20 million worth of its shares.Cathay Biotech Inc. announces a share repurchase program. Under the program, the company will repurchase up to CNY 20 million worth of its shares. The shares will be repurchased at a price of not more than CNY 67 per share. The repurchased shares will be used for employee stock ownership plans or equity incentives. Repurchases will be funded using company's own funds or self-raised funds. The program will be valid till 12 months from approval of board.
Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to CN¥46.38, the stock trades at a trailing P/E ratio of 72.5x. Average trailing P/E is 31x in the Chemicals industry in China. Total loss to shareholders of 13% over the past year.
お知らせ • Sep 30Cathay Biotech Inc. to Report Q3, 2024 Results on Oct 31, 2024Cathay Biotech Inc. announced that they will report Q3, 2024 results on Oct 31, 2024
Valuation Update With 7 Day Price Move • Sep 27Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥38.08, the stock trades at a trailing P/E ratio of 63.6x. Average trailing P/E is 29x in the Chemicals industry in China. Total loss to shareholders of 31% over the past year.
Reported Earnings • Aug 16Second quarter 2024 earnings released: EPS: CN¥0.24 (vs CN¥0.30 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.24 (down from CN¥0.30 in 2Q 2023). Revenue: CN¥759.8m (up 45% from 2Q 2023). Net income: CN¥142.2m (down 23% from 2Q 2023). Profit margin: 19% (down from 35% in 2Q 2023). The decrease in margin was driven by higher expenses.
お知らせ • Jun 28Cathay Biotech Inc. to Report First Half, 2024 Results on Aug 31, 2024Cathay Biotech Inc. announced that they will report first half, 2024 results on Aug 31, 2024
お知らせ • Jun 06Cathay Biotech Inc., Annual General Meeting, Jun 27, 2024Cathay Biotech Inc., Annual General Meeting, Jun 27, 2024, at 14:00 China Standard Time. Location: 9F, No. 11, Lane 396, Lvzhou Ring Road, Minhang District, Shanghai China
Reported Earnings • May 01First quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.10 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.18 (up from CN¥0.10 in 1Q 2023). Revenue: CN¥684.5m (up 35% from 1Q 2023). Net income: CN¥105.3m (up 83% from 1Q 2023). Profit margin: 15% (up from 11% in 1Q 2023). The increase in margin was driven by higher revenue.
Valuation Update With 7 Day Price Move • Apr 29Investor sentiment improves as stock rises 21%After last week's 21% share price gain to CN¥49.16, the stock trades at a trailing P/E ratio of 78.1x. Average trailing P/E is 32x in the Chemicals industry in China. Total loss to shareholders of 7.2% over the past year.
New Risk • Apr 09New major risk - Revenue and earnings growthEarnings have declined by 0.06% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.
お知らせ • Mar 30Cathay Biotech Inc. to Report Q1, 2024 Results on Apr 30, 2024Cathay Biotech Inc. announced that they will report Q1, 2024 results on Apr 30, 2024
Reported Earnings • Feb 24Full year 2023 earnings released: EPS: CN¥0.63 (vs CN¥0.95 in FY 2022)Full year 2023 results: EPS: CN¥0.63 (down from CN¥0.95 in FY 2022). Revenue: CN¥2.11b (down 13% from FY 2022). Net income: CN¥367.0m (down 34% from FY 2022). Profit margin: 17% (down from 23% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 49% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Chemicals industry in China.
お知らせ • Dec 29Cathay Biotech Inc. to Report Fiscal Year 2023 Results on Apr 30, 2024Cathay Biotech Inc. announced that they will report fiscal year 2023 results on Apr 30, 2024
Reported Earnings • Nov 02Third quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.25 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.13 (down from CN¥0.25 in 3Q 2022). Revenue: CN¥535.1m (down 2.5% from 3Q 2022). Net income: CN¥72.0m (down 52% from 3Q 2022). Profit margin: 14% (down from 27% in 3Q 2022). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 53% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Chemicals industry in China.
お知らせ • Aug 18Cathay Biotech Inc. (SHSE:688065) announces an Equity Buyback for CNY 100 million worth of its shares.Cathay Biotech Inc. announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The program will be valid for a period of 12 months.
Reported Earnings • Aug 08Second quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.28 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.30 (up from CN¥0.28 in 2Q 2022). Revenue: CN¥525.0m (down 16% from 2Q 2022). Net income: CN¥184.4m (up 14% from 2Q 2022). Profit margin: 35% (up from 26% in 2Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China.
お知らせ • Jun 28Cathay Biotech Inc. to Report First Half, 2023 Results on Aug 16, 2023Cathay Biotech Inc. announced that they will report first half, 2023 results on Aug 16, 2023
お知らせ • Jun 27Cathay Biotech Inc. announced that it expects to receive CNY 6.6 billion in funding from China Merchants Group LimitedCathay Biotech Inc. announced a private placement of common shares for gross proceeds up to CNY 6,600 million on June 25, 2023. The transaction will include participation from new investor China Merchants Group Limited. The transaction is subject to the approval of shareholders of the company.
Reported Earnings • Apr 26Full year 2022 earnings released: EPS: CN¥0.95 (vs CN¥1.04 in FY 2021)Full year 2022 results: EPS: CN¥0.95 (down from CN¥1.04 in FY 2021). Revenue: CN¥2.44b (up 11% from FY 2021). Net income: CN¥553.3m (down 9.0% from FY 2021). Profit margin: 23% (down from 28% in FY 2021). The decrease in margin was driven by higher expenses.
Board Change • Mar 15Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. 3 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.